Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

NCT01794845 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

NCT NCT01794845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01794845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
Lead sponsor
University of Miami
Phase
Phase 2
Overall status
Terminated
Start date
June 3, 2013
Completion date
June 7, 2016
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, recurrent disease, squamous cell carcinoma